Protara Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1,208 |
Gross Profit | -83 | -83 | 1,101 | |
EBITDA | -12,330 | -10,578 | -11,768 | -10,934 |
EBIT | -12,414 | -10,661 | -11,851 | -11,041 |
Net Income | -11,219 | -9,513 | -11,095 | -10,221 |
Net Change In Cash | 0 | 0 | 0 | 1,208 |
Free Cash Flow | -8,442 | -7,742 | -10,379 | -8,700 |
Cash | 51,757 | 89,581 | 52,231 | 39,586 |
Basic Shares | 22,329 | 21,233 | 11,420 | 11,364 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -341 | -247 | -1,167 | -196 |
EBITDA | -43,272 | -64,568 | -46,085 | -33,782 |
EBIT | -43,613 | -64,815 | -47,252 | -33,978 |
Net Income | -40,420 | -64,815 | -47,135 | -33,512 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 168,829 | |||
Free Cash Flow | -37,602 | -26,577 | -35,098 | -24,291 |
Cash | 39,586 | 24,127 | 35,724 | 168,598 |
Basic Shares | 11,331 | 11,259 | 11,232 | 7,233 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.50 |
2024-06-30 | -$0.45 |
2024-03-31 | -$0.97 |
2023-12-31 | -$0.90 |
